Disease · MONDO_0005366
Comparisons in its trials64
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 64
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| TDF-TDF vs ADV-TDF: deaths from any cause | 1 of 257 | 0 of 252 | 509 | NCT01300234 | Trial comparisons |
| TDF-TDF vs ADV-TDF: serious adverse events | 12 of 257 | 20 of 252 | 509 | NCT01300234 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Serious Adverse Events | 11 of 102 | 7 of 99 | 201 | NCT01369212 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Adverse Events | 50 of 102 | 60 of 99 | 201 | NCT01369212 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: deaths from any cause | 0 of 102 | 0 of 99 | 201 | NCT01369212 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: serious adverse events | 11 of 102 | 7 of 99 | 201 | NCT01369212 | Trial comparisons |
| Peginterferon Alfa-2a + Entecavir vs Entecavir: serious adverse events | 6 of 97 | 0 of 100 | 197 | NCT00940485 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBsAg Seroconversion at Week 192 | 1 of 96 | 4 of 92 | 188 | NCT01369212 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Alanine Transaminase(ALT) Levels <= 38 U/L for Males and <=25 for Females at Week 192 | 58 of 96 | 72 of 91 | 187 | NCT01369212 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Normal Alanine Transaminase (ALT) Levels at Week 192 | 37 of 96 | 51 of 91 | 187 | NCT01369212 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBV DNA<1000 IU/mL at Week 192 | 95 of 96 | 90 of 91 | 187 | NCT01369212 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBV DNA<20 IU/mL at Week 192 | 82 of 96 | 87 of 91 | 187 | NCT01369212 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Normal Alanine Transaminase (ALT) Levels at Week 240 | 38 of 92 | 41 of 89 | 181 | NCT01369212 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBV DNA<1000 IU/mL at Week 240 | 66 of 92 | 65 of 89 | 181 | NCT01369212 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBV DNA<20 IU/mL at Week 240 | 46 of 92 | 48 of 89 | 181 | NCT01369212 | Trial comparisons |
| ETV (Entecavir) vs PLACEBO: deaths from any cause | 0 of 120 | 0 of 60 | 180 | NCT01079806 | Trial comparisons |
| ETV (Entecavir) vs PLACEBO: serious adverse events | 4 of 120 | 9 of 60 | 180 | NCT01079806 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBsAg Seroconversion at Week 240 | 2 of 91 | 4 of 89 | 180 | NCT01369212 | Trial comparisons |
| TDF 300 mg OD vs ETV 0.5 mg OD: Number of Participants With Virological Breakthrough Through End of the Study | 2 of 109 | 2 of 56 | 165 | NCT01480284 | Trial comparisons |
| TDF 300 mg OD vs ETV 0.5 mg OD: serious adverse events | 7 of 109 | 2 of 56 | 165 | NCT01480284 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005366/comparisons